NATICK, Mass., March 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the annual American College of Cardiology (ACC) Scientific Session and i2 Summit, which runs from March 24 to 27 in New Orleans.

"We expect the most recent clinical data on the TAXUS® Express2™ Coronary Stent will further reinforce its market-leading position," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "With the recent addition of our Everolimus-based PROMUS™ Stent, we are the first company to offer complementary drug-eluting stent technologies to satisfy a broader range of physician's preferred treatment methods." (PROMUS is a private-labeled XIENCE™ V Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific.)

  Schedule of Events (all times are CT)

  Saturday, March 24
  -- Spirit III Trial Results -- XIENCE V (PROMUS) Stent and TAXUS Stent.
     At 11:30 a.m., results from Abbott's Spirit III clinical trial will be
     presented by Gregg W. Stone, M.D. at a Late Breaking trial session in
     room La Nouvelle Orleans C.  Dr. Stone will provide an analysis of
     eight and nine-month data on 1,002 patients treated with the XIENCE V
     (PROMUS) Stent or the TAXUS Express2 Stent.  SPIRIT III is a large-
     scale, non-inferiority, U.S. pivotal trial.  The Company plans to
     issue a press release at this time.

  Sunday, March 25
  -- TAXUS Meta-Analysis update.  Results from the four-year TAXUS Stent
     meta-analysis will be presented in an e-poster session at 11:00 a.m. by
     Dr. Stone in Hall H.  The independent meta-analysis will report data on
     the TAXUS stent from the TAXUS I, II, IV, V and VI trials that studied
     more than 3,500 patients.  The Company plans to issue a press release
     at this time.
  -- ARRIVE I Registry data.  The Company will release two-year results from
     its ARRIVE I registry, which has enrolled nearly 2,600 consecutive
     patients at 50 sites in the United States.  The program is designed
     to collect and analyze "real-world" safety and clinical outcomes data
     from the TAXUS Express2 paclitaxel-eluting stent system in the
     treatment of patients with coronary artery disease.  The results will
     be presented by John M. Lasala, M.D., PhD, FACC, at 12:00 p.m. at an e-
     poster session in Hall H.  The Company plans to issue a press release
     at this time.
  -- TAXUS V ISR Results.  The Company will release two-year results from
     the TAXUS V In-Stent Restenosis (ISR) clinical trial, which evaluates
     the TAXUS Express2 paclitaxel-eluting coronary stent system versus
     vascular brachytherapy for the treatment of bare-metal stent in-stent
     restenosis.  The TAXUS V ISR trial is a prospective, randomized, open-
     label trial that has enrolled 396 patients at 37 sites in the U.S.  The
     results will be presented by Stephen G. Ellis, M.D., at 2:30 p.m. at a
     poster session in Hall H.  The Company plans to issue a press release
     at this time.
  -- Symposium on Drug-Eluting Stents.  From 8:00-9:15 p.m., the Company
     will host a symposium entitled, "Boston Scientific Leadership in Three
     Dimensions" in Ballroom D of the Hilton New Orleans Riverside, Two
     Poydras Street, New Orleans.  The symposium will include presentations
     by Dr. Stone (Understanding the 2007 DES Clinical Data Landscape),
     Donald S. Baim, M.D., James B. Hermiller, M.D., FACC, FSCAI, and Dr.
     Lasala (PCI Patient Management), and Martin B. Leon, M.D. (Drug-Eluting
     Stent Evolution).  The Company will also host a reception prior to the
     symposium at 7:00 p.m.

  Monday, March 26
  -- BTK-CHILL 12-month data.  At 7:30 a.m., Tony S. Das, M.D., will present
     12-month results from the Below-The-Knee (BTK) CHILL trial in a podium
     session.  This prospective, multi-center trial is designed to evaluate
     the PolarCath™ Peripheral Dilatation System for restoring blood flow
     and reducing amputation in patients with critical limb ischemia.  The
     Company plans to issue a press release at this time.
  -- Analyst Meeting.  From 7:30-9:00 a.m., the Company will host an analyst
     meeting in Ballroom D of the Hilton New Orleans Riverside, Two Poydras
     Street, New Orleans.  The meeting is open to the media.  Registration
     is required for admittance.  This meeting is being webcast and can be
     accessed at Boston Scientific's website, http://www.bostonscientific.com/.
     Please visit the website for details on how to access the webcast.  A
     replay of the webcast will be archived and available in the Webcast and
     Archives section of the Investor Relations site at
     http://www.bostonscientific.com/.

Boston Scientific will present its latest innovations at booth #3733 in the Exhibit Hall, including its drug-eluting stent and carotid stent technologies, and LATITUDE® Remote Patient Management system for implantable cardiac device patients. The booth will also include a physician resource and patient education area as well as interactive product displays.

PROMUS, TAXUS, Express and Express2 are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott. The SPIRIT Clinical Program is sponsored by Abbott. The PROMUS Stent is not approved for sale in the U.S.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

   CONTACT: Paul Donovan
            508-650-8541 (office)
            508-667-5165 (mobile)
            Media Relations
            Boston Scientific Corporation

            Dan Brennan
            508-650-8538 (office)
            617-459-2703 (mobile)
            Investor Relations
            Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541 (office), or +1-
508-667-5165 (mobile), or Dan Brennan, Investor Relations, +1-508-650-8538
(office), +1-617-459-2703 (mobile), both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com/